Trial Profile

A study to assess immunogenicity of third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Sep 2022 Results (n=314) assessing slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine, published in the Journal of Infectious Diseases
14 Jun 2022 New trial record
08 Jun 2022 Results published in the Clinical Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com